Biogenic silver nanoparticles: in vitro and in vivo antitumor activity in bladder cancer. - GreenMedInfo Summary
Biogenic silver nanoparticles: in vitro and in vivo antitumor activity in bladder cancer.
Eur J Pharm Biopharm. 2020 Apr 17. Epub 2020 Apr 17. PMID: 32311428
Luiz Alberto Bandeira Ferreira
ladder cancer is the fifth most common disease in the United States, and the treatment and alternatives for patients have not changed in the last decades. Silver nanoparticles (AgNP) have been used in the treatment of various cancer, mainly because of the antineoplastic activity; however, their use and the molecular mechanisms towards bladder cancer still unexplored. Therefore, this work aims to evaluate in vitro and in vivo the antitumoral mechanisms of biogenic silver nanoparticles synthesized from Fusarium sp. First, AgNP showed cytotoxicity in a dose- and time-response relationship, and detailed analysis demonstrated the induction of cell death via apoptosis, also inhibiting cell migration and proliferation. Next, it was evaluated the antitumoral activity of AgNP against non-muscle invasive bladder cancer (NMIBC). Bladder cancer was chemically induced with N-methyl-N-nitrosourea (MNU) on C57BL/6Junib female mice and treated by intravesical route with AgNP concentrations of 0.5, 0.2, and 0.05 mg/mL. Finally, treatment with AgNP (0.05 mg/mL) led to 57.13% of tumor regression, with 14.28% of the animals showing normal urothelium and 42.85% showing flat hyperplasia, considered to be a benign lesion. Overall, these findings demonstrated that AgNP might be a cost-effective alternative and promising candidate for the treatment of bladder cancer.